biostudies-literatureKhalighi MNCATS NIH HHS204-209https://www.ebi.ac.uk/biostudies/studies/S-EPMC9329177biostudies-literatureUnknown71(2)<h4>Purpose</h4>The aim of this study is to compare the patient-reported bleeding outcomes and complication rates with the use of the 52-mg levonorgestrel-releasing intrauterine system (52-LNG-IUS) for treatment of heavy menstrual bleeding (HMB) among adolescents with and without a diagnosed inherited bleeding disorder (BD) within the first 12 months after insertion.<h4>Methods</h4>Retrospective chart review was conducted of adolescents ages 14-21 years, with and without an inherited BD, who underwent 52-LNG-IUS insertion between September 2013 and February 2020 for the treatment of HMB.<h4>Results</h4>One hundred forty-four 52-LNG-IUS insertions among 139 subjects were evaluated. Fifty-nine (41%) of these were among adolescents with a diagnosed inherited BD, and 85 (59%) were among those The Journal of adolescent health : official publication of the Society for Adolescent MedicineDoes a Bleeding Disorder Lessen the Efficacy of the 52-mg Levonorgestrel-Releasing Intrauterine System for Heavy Menstrual Bleeding in Adolescents? A Retrospective Multicenter Study.PMC9329177UL1 TR001855Durazo-Arvizu RAKouides PAKhalighi MAdeyemi-Fowode OADersch CMWheeler APHaley KWeyand ACBorzutzky CBaldwin MKfalseDoes a Bleeding Disorder Lessen the Efficacy of the 52-mg Levonorgestrel-Releasing Intrauterine System for Heavy Menstrual Bleeding in Adolescents? A Retrospective Multicenter Study.<h4>Purpose</h4>The aim of this study is to compare the patient-reported bleeding outcomes and complication rates with the use of the 52-mg levonorgestrel-releasing intrauterine system (52-LNG-IUS) for treatment of heavy menstrual bleeding (HMB) among adolescents with and without a diagnosed inherited bleeding disorder (BD) within the first 12 months after insertion.<h4>Methods</h4>Retrospective chart review was conducted of adolescents ages 14-21 years, with and without an inherited BD, who underwent 52-LNG-IUS insertion between September 2013 and February 2020 for the treatment of HMB.<h4>Results</h4>One hundred forty-four 52-LNG-IUS insertions among 139 subjects were evaluated. Fifty-nine (41%) of these were among adolescents with a diagnosed inherited BD, and 85 (59%) were among those 2022-01-01T00:00:00Z2022 Aug2025-04-04T20:07:06.593Z2025-04-04T20:07:06.593ZS-EPMC93291773543014310.1016/j.jadohealth.2022.02.018